Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 10, Issue 1, Pages 180
Publisher
Springer Nature
Online
2012-08-31
DOI
10.1186/1479-5876-10-180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma
- (2011) Tobias Lange et al. CANCER LETTERS
- Multidisciplinary Management of Early and Locally Advanced Esophageal Cancer
- (2011) Jussuf T. Kaifi et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
- (2010) F. Nemati et al. CLINICAL CANCER RESEARCH
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Effective Therapeutic Targeting of the Overexpressed HER-2 Receptor in a Highly Metastatic Orthotopic Model of Esophageal Carcinoma
- (2010) S. J. Gros et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry
- (2009) Yukie Sato-Kuwabara et al. BMC CANCER
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor
- (2009) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma
- (2009) Ioannis D. Lyronis et al. PATHOLOGY & ONCOLOGY RESEARCH
- Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
- (2009) Masafumi Kurosumi Breast Cancer
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
- (2008) I. Fichtner et al. CLINICAL CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- PIK3CA Mutation Status in Japanese Esophageal Squamous Cell Carcinoma
- (2008) Ryota Mori et al. JOURNAL OF SURGICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More